

# Specialty Guideline Management

## Onapgo

### Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Onapgo	apomorphine hydrochloride

### Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

#### FDA-approved Indications<sup>1</sup>

Onapgo is indicated for the treatment of motor fluctuations in adults with advanced Parkinson's disease.

All other indications are considered experimental/investigational and not medically necessary.

# Coverage Criteria

## Parkinson's Disease<sup>1,2</sup>

Authorization of 6 months may be granted for treatment of motor fluctuations in members with advanced Parkinson's disease when all of the following criteria are met:

- Member has clearly defined "on" periods.
- The member has "off" periods of at least 3 hours per day despite optimization efforts.
- The member must have had an inadequate response or intolerable adverse event with oral carbidopa/levodopa and one of the following anti-Parkinson agents:
  - Dopamine agonist (e.g., pramipexole, ropinirole)
  - Monoamine oxidase-B (MAO-B) inhibitor (e.g., selegiline, rasagiline)
  - Catechol-O-methyltransferase (COMT) inhibitor (e.g., entacapone, tolcapone)

## Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for advanced Parkinson's disease who have demonstrated a positive clinical response with the requested medication.

## References

1. Onapgo [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc.; February 2025.
2. National Institute for Health and Care Excellence (NICE) guideline: Parkinson's disease in adults. Published July 19, 2017. Accessed February 12, 2025.  
<https://www.nice.org.uk/guidance/ng71/resources/parkinsons-disease-in-adults-pdf-1837629189061>.